Crescent Biopharma (CBIO) Net Cash Flow Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 89.97% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -13.44% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 33.37% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -29.82% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 32.17% |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | -50.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.38% |
| Dec 31, 2025 | 129.62% |
| Sep 30, 2025 | -30.90% |
| Jun 30, 2025 | 115.49% |
| Mar 31, 2025 | 3.52% |
| Dec 31, 2024 | 70.76% |
| Jun 30, 2024 | 13.23% |
| Mar 31, 2024 | -32.06% |
| Dec 31, 2023 | -9.28% |
| Sep 30, 2023 | -7.36% |
| Jun 30, 2023 | -11.84% |
| Mar 31, 2023 | 91.94% |
| Dec 31, 2022 | 14.56% |
| Sep 30, 2022 | 13.42% |
| Jun 30, 2022 | -12.61% |
| Mar 31, 2022 | 1.46% |
| Dec 31, 2021 | -5.59% |
| Sep 30, 2021 | -20.79% |
| Jun 30, 2021 | -1.05% |
| Mar 31, 2021 | -26.79% |
| Dec 31, 2020 | -36.23% |
| Sep 30, 2020 | -3.58% |
| Jun 30, 2020 | -27.22% |
| Mar 31, 2020 | 14.74% |
| Dec 31, 2019 | -34.27% |
| Sep 30, 2019 | -19.40% |
| Jun 30, 2019 | -40.93% |
| Mar 31, 2019 | -21.66% |
| Dec 31, 2018 | -12.52% |
| Sep 30, 2018 | -39.42% |
| Jun 30, 2018 | -27.73% |
| Mar 31, 2018 | 150.68% |
| Dec 31, 2017 | 55.96% |
| Sep 30, 2017 | -8.93% |
| Jun 30, 2017 | 109.08% |
| Mar 31, 2017 | -28.05% |
| Dec 31, 2016 | 0.86% |
| Sep 30, 2016 | -36.20% |
| Jun 30, 2016 | 93.27% |
| Mar 31, 2016 | -27.10% |